Attributes | Values |
---|
rdf:type
| |
Description
| - The efficacy and safety of prostacyclin (PGI(2)) and citrate (ACD) anticoagulation were observed and compared during continuous haemodiafiltration. Methods: Mechanically ventilated patients received either the PGI(2) analogue epoprostenol (group A, n = 17) in escalating doses of 4.5 - 10.0 ng center dot kg(-1) center dot min(-1) in combination with heparin (6 IU center dot kg(-1) center dot h(-1)) or 2.2% ACD ( group B, n = 15). Blood flow was set to match the circuit-filling volume per unit time equal to the intravascular half-life of PGI(2). Results: Median filter lifetimes were 26 h (interquartile range 16 - 37) in group A ( 39 filters) and 36.5 h ( interquartile range 23 - 50) in group B (56 filters; p < 0.01). In group A, 4 patients (23.5%, p < 0.05) had the dose reduced due to hypotension. The final mean dose of PGI(2) was 8.7 +/- 2.4 ng center dot kg(-1) center dot min(-1). Four patients in group A (23.5%, p < 0.05) were switched to ACD due to a decrease in platelet count. No bleeding
- The efficacy and safety of prostacyclin (PGI(2)) and citrate (ACD) anticoagulation were observed and compared during continuous haemodiafiltration. Methods: Mechanically ventilated patients received either the PGI(2) analogue epoprostenol (group A, n = 17) in escalating doses of 4.5 - 10.0 ng center dot kg(-1) center dot min(-1) in combination with heparin (6 IU center dot kg(-1) center dot h(-1)) or 2.2% ACD ( group B, n = 15). Blood flow was set to match the circuit-filling volume per unit time equal to the intravascular half-life of PGI(2). Results: Median filter lifetimes were 26 h (interquartile range 16 - 37) in group A ( 39 filters) and 36.5 h ( interquartile range 23 - 50) in group B (56 filters; p < 0.01). In group A, 4 patients (23.5%, p < 0.05) had the dose reduced due to hypotension. The final mean dose of PGI(2) was 8.7 +/- 2.4 ng center dot kg(-1) center dot min(-1). Four patients in group A (23.5%, p < 0.05) were switched to ACD due to a decrease in platelet count. No bleeding (en)
|
Title
| - Prostacyclin versus citrate in continuous haemodiafiltration: An observational study in patients with high risk of bleeding
- Prostacyclin versus citrate in continuous haemodiafiltration: An observational study in patients with high risk of bleeding (en)
|
skos:prefLabel
| - Prostacyclin versus citrate in continuous haemodiafiltration: An observational study in patients with high risk of bleeding
- Prostacyclin versus citrate in continuous haemodiafiltration: An observational study in patients with high risk of bleeding (en)
|
skos:notation
| - RIV/00216208:11120/05:00002337!RIV11-MSM-11120___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/05:00002337
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - acute renal failure; renal replacement therapy; haemodiafiltration; prostacyclin; citrate (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - CH - Švýcarská konfederace
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Balík, Martin
- Waldauf, Petr
- Pachl, Jan
- Plášil, Petr
|
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |